Abd-Elfattah A S, Ding M, Wechsler A S
Department of Surgery, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0532.
J Card Surg. 1993 Mar;8(2 Suppl):257-61. doi: 10.1111/j.1540-8191.1993.tb01319.x.
Mechanisms of myocardial stunning include myocardial adenosine triphosphate (ATP) depletion, catecholamine release, and oxygen free radical formation. Although the latter is the most widely supported mechanism, levels of 5'-nucleotidase (directs AMP dephosphorylation) are inversely related to functional recovery following ischemia and may also have a role in ischemic injury. Previous studies reveal that 5'-nucleotidase levels increase with age and also vary with species. An inhibitor of this enzyme (alpha, beta methylene adenosine 5'-diphosphate) was effective in maintaining AMP levels in vitro but was ineffective in dogs due to limited permeability. Observed species-specific differences in recovery from myocardial stunning may be related to differences in AMP accumulation and subsequent metabolism. Species showing improved recovery from stunning may accumulate AMP as a result of feedback inhibition of 5'-nucleotidase. Using a model of extreme experimentally-induced ischemia, we found that adenosine treatment allowed full recovery of ventricular function within 30 minutes, probably by entrapping ATP catabolites. Similarly, enhancement of adenosine production by N-diarylalkylpeprazine derivatives has also been shown to be cardioprotective in the setting of global normothermic ischemia. Novel strategies for pharmacological intervention in the ATP catabolic pathway should use animal models involving species that are tolerant to myocardial stunning.
心肌顿抑的机制包括心肌三磷酸腺苷(ATP)耗竭、儿茶酚胺释放和氧自由基形成。尽管后者是最广泛认可的机制,但5'-核苷酸酶(指导AMP去磷酸化)的水平与缺血后的功能恢复呈负相关,并且可能在缺血损伤中也起作用。先前的研究表明,5'-核苷酸酶水平随年龄增长而升高,并且也因物种而异。这种酶的一种抑制剂(α,β-亚甲基腺苷5'-二磷酸)在体外可有效维持AMP水平,但由于通透性有限,在犬类中无效。观察到的心肌顿抑恢复中的物种特异性差异可能与AMP积累及随后的代谢差异有关。从顿抑中恢复情况较好的物种可能由于5'-核苷酸酶的反馈抑制而积累AMP。使用极端实验性诱导缺血模型,我们发现腺苷治疗可使心室功能在30分钟内完全恢复,可能是通过捕获ATP分解代谢产物实现的。同样,在整体正常体温缺血情况下,N-二芳基烷基哌嗪衍生物增强腺苷生成也已显示具有心脏保护作用。ATP分解代谢途径的药理学干预新策略应使用涉及对心肌顿抑耐受物种的动物模型。